Skip to main content
. 2019 Aug 7;146(7):1917–1929. doi: 10.1002/ijc.32583

Table 4.

Progression‐free survival at second‐line treatment (PFS2) overall and according to molecular subtype and type of treatment received

Molecular subtype T‐DM1 as second‐line Median PFS (months, CI) p
Overall Yes 7 (5–9) 0.003
No 6 (5–7)
Triple‐positive Yes 6 (5–7) 0.17
No 6 (5–7)
ER‐ or PgR‐positive Yes 7 (4–10) 0.05
No 5 (3–7)
HRs‐negative Yes 10 (8–12) 0.04
No 7 (6–8)

Abbreviations: ER, estrogen receptor; PgR, progesterone receptor.